Full Press Release Details
Ownership in Radiopharm Ventures to 87.5%
Sydney, Australia - 12 January 2026 -
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused
on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased
its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center (MDACC),
Radiopharm's decision to increase the ownership
percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement
of its leading B7H3 candidate and other preclinical assets.
B7H3 is an immune checkpoint protein that is very
infrequently seen in healthy cells but is consistently overexpressed in the majority of cancer tissues. High expression of B7H3 in cancer
is associated with greater tumor size and lymphatic invasion.
Riccardo Canevari, CEO & Managing Director
of Radiopharm, commented: "We are very encouraged by the progress to date within Radiopharm Ventures. Now is an exciting time to
increase our ownership in the joint venture, as we will soon have first-in-human results of Betabart (RV01) from our dose escalating therapeutic
Phase I study. We remain confident in the potential value of this program and its potential to benefit patients battling a multitude of
solid tumor cancers."
The lead candidate monoclonal antibody (mAb) radiolabelled
with 177Lu, Betabart, targets B7H3 and successfully received Investigational New Drug clearance in July 2025 by the U.S. Food
and Drug Administration. The first patient in this Phase 1 therapeutic trial is expected to be dosed in Q1 2026, with a number of centers
Additionally, two other preclinical candidates
have demonstrated early positive results and have progressed towards final candidate selection, with potential applications across multiple
Radiopharm and MDACC launched Radiopharm Ventures,
LLC in September 2022 to develop novel radiopharmaceutical products for cancer treatment. The joint venture leverages MD Anderson's
expertise in antigen discovery and molecular imaging alongside Radiopharm's capabilities in developing targeted radiopharmaceutical
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage
radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic
applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of
distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer.
The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers, including lung, breast, and brain
metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm
Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
CEO & Managing Director
Precision AQ (Formerly Stern IR)
Follow Radiopharm Theranostics:
Website - https://radiopharmtheranostics.com/
Twitter - https://twitter.com/TeamRadiopharm
InvestorHub - https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia